Efficacy and Safety of VDPHL01 in Males With AGA
Public ClinicalTrials.gov record NCT06724614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). The first 7 visits will be part of the placebo-controlled period. The next 3 visits will be part of the treatment extension phase. All subjects will receive active drug in the treatment extension phase.
Study identification
- NCT ID
- NCT06724614
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 480 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 6, 2024 (Actual)
- Primary completion
- Feb 2026 (Estimated)
- Completion
- Sep 2026 (Estimated)
- Last update posted
- Nov 6, 2025
2024 – 2026
United States locations
- U.S. sites
- 44
- U.S. states
- 24
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 36 | Birmingham | Alabama | 35203 | — |
| Site 28 | Phoenix | Arizona | 85018 | — |
| Site 30 | Fort Smith | Arkansas | 72916 | — |
| Site 35 | Rogers | Arkansas | 72758 | — |
| Site 07 | Fountain Valley | California | 92728 | — |
| Site 02 | Fremont | California | 94538 | — |
| Site 34 | Sherman Oaks | California | 91403 | — |
| Site 21 | Vista | California | 92083 | — |
| Site 05 | Castle Rock | Colorado | 80109 | — |
| Site 24 | Englewood | Colorado | 80111 | — |
| Site 17 | Aventura | Florida | 33180 | — |
| Site 25 | Brandon | Florida | 33511 | — |
| Site 42 | Hollywood | Florida | 33021 | — |
| Site 03 | Tampa | Florida | 33613 | — |
| Site 43 | Atlanta | Georgia | 30329 | — |
| Site 31 | Boise | Idaho | 83704 | — |
| Site 23 | Rolling Meadows | Illinois | 60008 | — |
| Site 15 | Indianapolis | Indiana | 46250 | — |
| Site 32 | New Albany | Indiana | 47150 | — |
| Site 27 | West Lafayette | Indiana | 47906 | — |
| Site 41 | Baton Rouge | Louisiana | 70809 | — |
| Site 13 | Covington | Louisiana | 70433 | — |
| Site 12 | Metairie | Louisiana | 70006 | — |
| Site 22 | Brighton | Massachusetts | 02135 | — |
| Site 26 | Clarkston | Michigan | 48346 | — |
| Site 06 | New Brighton | Minnesota | 55112 | — |
| Site 18 | Hackensack | New Jersey | 07601 | — |
| Site 37 | Kew Gardens | New York | 11415 | — |
| Site 38 | New York | New York | 10075 | — |
| Site 39 | Boardman | Ohio | 44512 | — |
| Site 11 | Columbus | Ohio | 43215 | — |
| Site 08 | Broomall | Pennsylvania | 19073 | — |
| Site 10 | Plymouth Meeting | Pennsylvania | 19462 | — |
| Site 20 | Greensville | South Carolina | 29615 | — |
| Site 09 | Knoxville | Tennessee | 37909 | — |
| Site 16 | Murfreesboro | Tennessee | 37130 | — |
| Site 04 | Nashville | Tennessee | 37215 | — |
| Site 40 | Bellaire | Texas | 77401 | — |
| Site 44 | Dallas | Texas | 75231 | — |
| Site 14 | Houston | Texas | 77056 | — |
| Site 19 | West Jordan | Utah | 84095 | — |
| Site 29 | Lynchburg | Virginia | 24501 | — |
| Site 33 | Seattle | Washington | 98168 | — |
| Site 01 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06724614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 6, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06724614 live on ClinicalTrials.gov.